Pherin Pharmaceuticals, Inc.

VistaGen Therapeutics, Inc. suffered a significant setback last year when its lead drug candidate fasedienol (PH94B) for treatment of social anxiety disorder failed to meet the primary endpoint in th

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Mersana Ends 2022 With Third Big Pharma

VistaGen Therapeutics, Inc. has rebounded from clinical development setbacks before, but investors imposed a severe penalty on the South San Francisco biotech on 22 July following its pre-market anno

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in